Leukemia Clinical Trials

Showing 241-260 of 5,235 trials

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

NCT06228482

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).

Metastatic Nonsmall Cell Lung Cancer

University of California, Davis40 participantsStarted Jan 2024

Sacramento, California, United States

RECRUITINGPHASE2

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

NCT06511882

The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.

Acute Myeloid Leukemia

H. Lee Moffitt Cancer Center and Research Institute37 participantsStarted Nov 2024

Tampa, Florida, United States

RECRUITINGPHASE1

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

NCT06905197

This study is designed to evaluate safety and anti-tumor activity of DZD6008 in patients with advanced NSCLC with EGFR mutations.

Non Small Cell Lung Cancer

Dizal Pharmaceuticals140 participantsStarted May 2025

New York, New York, United States • New York, New York, United States • Fairfax, Virginia, United States +2 more locations

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Related Searches

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Evaluation of Small Vessel Disease by 3D-rotational Angiography

Pilot Study of Posaconazole in Crohn's Disease

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

Phase I Trial of MT-0169 in CD38+ Acute Leukemia With Relapsed/Refractory or Measurable Residual Disease

Human Breast Milk's Role in Food Allergy Development

Dual-Task vs. Multicomponent Exercise in Institutionalized Seniors

Online Watch-Summarize-Question-Ask Method in Falls Education for Nursing Students